Objective: Platelet activation in COPD patients is associated with an increased risk of cardiovascular events. We aimed at assessing the mean platelet volume (MPV), as an index of platelet activation, in COPD patients both when stable or during acute exacerbation (AE).
INTRODUCTION
An important association was observed between chronic obstructive pulmonary disease (COPD) and cardiovascular diseases [1, 2] , being events such as myocardial infarction [3] and stroke [4] more frequent in these patients than in the healthy population. Indeed, both COPD and cardiovascular diseases share common risk factors, smoking habit as most important [5] .
A large body of research aimed at finding the explanation of this enhanced risk in the COPD population, focusing in particular on systemic inflammation as a driving mechanism for atherothrombosis [6, 7] . Recent studies have shown the presence of increased platelet activation in patients with COPD [8] [9] [10] , which may be correlated with the presence of circulating inflammatory mediators and with the hypoxemia which is typical in the advanced stages of the disease [11] . The increased mean platelet volume (MPV) is an index of accelerated platelet activation, derives from the change of the platelets' shape, and leads to enhanced thrombosis [12] [13] . Very recently, it has been demonstrated that high MPV is correlated with higher risk of developing atherosclerotic thrombotic cardiovascular events, mainly in chronic patients suffering from diabetes, hypertension and obesity, where platelet activation is enhanced [14] . Moreover, in elderly male patients with COPD, the MVP was inversely correlated with the level of FEV 1 , and the impairment of cardiopulmonary function [15] .
In the present study we aimed at assessing the MPV value in a large population of COPD patients both when stable or during an episode of acute exacerbation (AE) and to determine whether correlation exists between MPV and the stage of disease severity, the systemic inflammation and the increased prevalence of atherothrombotic cardiovascular events in the studied population.
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METHODS
Study protocol
Four-hundred and seventy eight COPD patients admitted between April 2012 and December 2013, for different purposes (poorly controlled arterial hypertension, syncope, pleuritic chest pain, dizziness and disequilibrium, associated-disease disability), at both the Unit of Internal Medicine-Spedali Civili (Brescia), Rehabilitation Unit-Ospedale Villa Pineta (Pavullo n/F, MO), and Pneumology Unit-Ospedale San Luigi (Orbassano, TO) were retrospectively studied. Seventy-five of them were admitted due to an AE of the disease. This study complied with the Declaration of Helsinki and was approved by the local Review Board at each centre. A waiver of consent was granted, and patient identity was protected.
Diagnosis of COPD
Measurements
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Medical history, respiratory function tests, and blood analysis was recorded in each participant.
Active smoking was defined if a current use of >2 cigarettes/day was reported; the number of pack/year was also recorded.
Respiratory Function Tests-Lung spirometry was performed in accordance with the standard procedure [19] . Forced Vital Capacity (FVC) and Forced Expiratory Volume in the first second (FEV 1 ) were recorded.
Peripheral Blood analysis-Blood sample was taken at admission. Ten millilitres of fasting bloods were drawn from each subject enrolled, tubes containing the dipotassium salt of thylenediamine tetraacetic acid (EDTA) were used for measurement of MPV [20] . Samples were immediately taken to the Hospital central laboratory to be analysed.
Total count on platelets, red and white cell, the MPV, and the level of both erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were recorded for study purposes. The inter-and intra-assays coefficients of variation of these assays were below 5%.
Co-morbidities-Co-existing chronic diseases were identified by examining the clinical documentation provided by each subject at admission and/or by the results from diagnostic tests performed during hospitalization.
Diabetes mellitus was diagnosed if plasma glucose > 126 mg/dL, and/or treatment with antidiabetic drugs, and/or presence of haemoglobin A1c > 6.5% [21, 22] . Obesity was defined when BMI was greater than or equal to 30.
The presence of cerebrovascular disease was based on the past medical history of cerebral infarction, cerebral thrombosis, transient ischemic attack, artery occlusion at the carotid or vertebral vessels.
Statistical Analysis
Data were presented as mean ± standard deviation (SD). Subjects were analysed according to different groups (stable or exacerbated COPD and Controls) or categories (presence of at least one cardiovascular co-morbidity, MPV value ≥10.5 fL as the median cut-off of distribution).
After verifying that data were normally distributed, group comparisons were performed using t-test for independent variables. Analysis of correlation among variables was performed by linear regression with a straight trend and through the calculation of Pearson coefficient. Categorical variables were compared by the chi-square test method.
A p value <0.05 was considered to be significant. All analysed were performed with a dedicated software (SPSS 21.0 for Windows; SPSS, Chicago, IL).
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RESULTS
Characteristics of subjects in study are displayed in Table 1 . Most of the COPD patients were in stage II or III according to the post bronchodilator FEV 1 . Seventy-five patients were under AE, being twenty-five (33%) of them in stage IV of the disease.
Chronic co-morbidities were similar between COPD and controls, as well as the use of antiaggregants and/or anticoagulants was similar.
Two-hundred twenty seven (47.4%) out of the 478 COPD patients (192/403 stable and 35/75 during AE) had at least one cardiovascular disease (hypertension, acute myocardial infarction, exertional angina, coronary artery disease, cerebral vascular disease, arterial disease of the lower limbs, thromboembolic disease). The proportion of patients with at least one cardiovascular co-morbidity was also similar (48.6%) in the control group.
Two-hundred fifty eight COPD were taking acetylsalicylic acid (ASA) as an antiplatelet therapy (11 subjects were under dual antiplatelet therapy with ASA and clopidogrel); 89 patients were receiving anticoagulation therapy with warfarin (n=86) or enoxaparin (n=3). Forty-one out of 72 controls were receiving ASA (one subject was under dual therapy with ASA and clopidogrel), while 11 were assuming warfarin. No difference was noted in the medication taken in the group of COPD patients under AE compared to the group of COPD patients in stable condition. Table 2 resumes data of both lung function and peripheral blood in the study groups. In particular, the mean MPV differed significantly between COPD patients taken together and controls (respectively 8.7 ± 1.1 fL and 8.4 ± 0.8 fL in COPD patients and in controls p = 0.025), despite platelet count was similar. The mean values of ESR and PCR were similar in patients and in controls (see Table 2 ).
Noteworthy, we observed an inverse correlation between the platelets count and the MPV in patients with COPD (Pearson = -0.115, p <0.05, Figure 1 ) but not in controls (Pearson = -0.009, ns).
Mean MPV did not correlate with ESR, PCR, the total number of co-morbidities and the use of Sub-group analysis: COPD patients without or with AE. Table 3 and Figure 2 show comparison of mean MPV value between study groups including COPD with or without AE. In COPD patients, MPV level was lower when stable as compared during AE (8.7 ± 1.0 fL, and 8.9 ± 1.0 fL respectively, p = 0.021). Moreover, MPV was higher in COPD stage II to IV when compared with stage I (see Table 3 Finally, the presence of a MPV ≥10.5 fL significantly correlated with the presence of at least one cardiovascular co-morbidity in COPD patients taken together (but not in controls) (see Table 4 ). The increased values of MPV could follow the hypoxemia that is typical in patients with COPD, in particular at peripheral tissue level, which may trigger bone marrow stimulation or increase the sequestration of smaller platelets [28] . COPD is associated with systemic inflammation, oxidative stress, activation of circulating inflammatory cells and increased levels of inflammatory mediators, mechanisms that may be partly responsible of platelet activation as observed in COPD [29, 31] ,
where the presence of a pro-thrombotic state with high production of thrombin and pro-coagulative mediators was reported [34].
By confirming previous data on increased MPV in the COPD population, present study is the first to show that it is present in the more severe stages of the disease and/or during AE. Therefore, the severity of COPD is possibly associated with a progressive increase of MPV, despite the pathophysiological mechanism(s) involved, among all those mentioned above, has not yet been . This study also advanced the concrete hypothesis that COPD may be an independent predictor for the presence of carotid atherosclerosis.
Despite our findings in a consistent population of COPD confirm the role of platelet activation in the disease and also clarify the concept that this happens according to the degree of severity and during AE, present study has some limitations that deserves to be outlined. A first potential limit is the retrospective design, thus a selection bias (e.g. the similar systemic inflammation level in both groups) may have occurred. Second, we were not able to report a patent cause-effect relationship To test this hypothesis, however, further prospective studies on larger populations are needed.
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